Open AccessBiomarkers for therapy selection in metastatic urothelial cancer
Author(s) -
Tomi Jun,
Jonathan F. Anker,
Matthew D. Galsky
Publication year - 2022
Publication title -
journal of cancer metastasis and treatment
Language(s) - English
Resource type - Journals
ISSN - 2394-4722
DOI - 10.20517/2394-4722.2021.171
Subject(s) - urothelial cancer , targeted therapy , biomarker , immunotherapy , medicine , cancer , drug development , oncology , clinical trial , chemotherapy , cancer research , drug , bladder cancer , biology , pharmacology , biochemistry
The treatment of metastatic urothelial cancer (mUC) has been transformed by recent progress in clinical trials and drug development. There are now three therapeutic classes with proven benefits in mUC: chemotherapy, immunotherapy, and targeted therapy. The optimal sequence and combination of these classes remain to be defined. Biomarker development is essential to guide treatment selection at each therapeutic juncture. Two biomarkers, programmed death-ligand 1 expression and fibroblast growth factor receptor alterations, have been incorporated into the mUC treatment paradigm thus far. This review discusses predictive biomarkers in development and their potential to influence mUC treatment selection moving forward.